

ACL Laboratories COVID-19 and Influenza Activity Report


Updated: Nov 28, 2021



RESPIRATORY PATHOGEN PANEL Nov 28, 2021 Positivity Rate (%)



MONTH	FLU A	FLU A (H1N1)	2009 H1N1	FLU A H3N2	FLU B	RSV A	RSV B	RSV A/B	PARA 1	PARA 2	PARA 3	Para 4	COR 229E	COR NL63	COR OC43	COR HKU1	META	E/R	Adeno	BOCA	Legio nella	Chla mydia	Myco plasma
JAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.1	0.7	0.3	0.0	0.0	0.0
FEB	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.2	6.1	0.2	0.3	0.0	0.0	0.0
MAR	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.4	0.1	0.1	0.3	0.1	1.4	0.9	0.1	0.4	12.2	1.2	0.3	0.0	0.1	0.1
APR	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.5	0.0	0.0	2.5	2.9	0.0	0.8	15.3	1.4	1.2	0.0	0.0	0.0
MAY	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.7	3.9	0.0	0.2	1.4	3.9	0.0	0.0	14.4	1.7	1.4	0.2	0.0	0.1
JUN	0.0	0.0	0.0	0.0	0.0	0.1	1.8	1.9	0.0	0.3	9.6	0.0	0.3	0.4	2.4	0.0	0.1	15.8	1.1	1.8	0.0	0.0	0.1
JUL	0.0	0.0	0.0	0.0	0.0	1.0	7.2	8.2	0.1	0.5	12.9	0.0	0.1	0.4	1.4	0.0	0.5	18.9	1.6	4.4	0.4	0.0	0.0
AUG	0.0	0.0	0.0	0.0	0.0	0.8	12.5	13.3	0.0	1.2	6.2	0.1	0.1	0.1	0.5	0.0	0.7	14.0	1.3	3.6	0.0	0.0	0.0
SEP	0.0	0.0	0.0	0.0	0.0	0.7	10.6	11.3	0.0	0.9	1.8	0.4	0.0	0.0	0.4	0.0	0.6	23.6	0.8	4.1	0.1	0.0	0.1
OCT	0.0	0.0	0.0	0.0	0.0	0.5	7.3	7.8	0.0	1.6	1.2	1.0	0.1	0.0	0.4	0.0	0.3	21.0	1.2	4.0	0.2	0.0	0.0
NOV	0.0	0.0	0.1	0.4	0.0	0.3	7.5	7.8	0.1	1.6	1.0	1.5	0.2	0.0	0.9	0.0	1.1	18.2	1.3	3.8	0.1	0.0	0.0
DEC																							

Increased prevalence of viruses: **Rhinovirus, RSV, Boca virus and Parainfluenza type 2 and 4**



ACL RSV positivity rate - trends down

CDC Data RSV pos rate for Region 5 Chicago - (PCR – 14%↓, Antigen - 13% ↓)




CDC RSV positivity rate - trends down

SARS-COV-2				Influenza PCR		RSV PCR		
Week	IL % SCVPCR	WI % SCVPCR	IL % COVAG	WI % COVAG	IL % FLUPCR	WI % FLUPCR	IL % RSVPCR	WI % RSVPCR
Nov 21	8.8	10.6	12.8	18.9	3.9	1.8	10.2	9.8
Nov 21	5.8	10.3	8.5	20.2	1.9	0.2	14.0	12.0
Nov 14	4.7	9.0	7.5	21.7	0.5	0	15.0	15.7
Nov 7	3.8	7.4	6.6	17.6	0	0.3	21.4	20.7
Oct 31	3.8	6.3	4.8	13.7	0.3	0	20.9	32.2
Oct 24	3.7	5.6	5.1	16.7	0	0.2	22.5	30.6
Oct 17	3.7	6.5	7.0	18.0	0	0	27.0	31.3
Oct 10	4.3	7.6	5.0	18.2	0	0.2	23.9	32.6
Oct 3	5.0	8.6	6.0	16.6	0	0	24.9	35.5
Sep 26	5.0	8.1	4.4	15.2	0	0	30.0	37.7
Sep 18	4.9	9.0	7.2	17.5	0	0	28.0	39.6
Sep 12	6.5	9.6	5.9	20.5	0	0	41.6	43.7
Sep 5	6.2	8.3	7.0	22.4	0	0	38.1	40.5


ACL Flu PCR tests results are consistent with beginning of “Flu season”

ACL COVAG and SCVPCR - Pos rate (%) - Nov 28, 2021




ACL SARS-CoV-2 positivity rate - trends up

CDC- Daily COVID-19 cases in US – Nov 17, 2021



CDC Covid positivity rate - trends up


Nov 13, 2021 – SARS-CoV-2 circulating in the US (~99.9% % Delta variants)



US vaccination status CDC | Data as of: Nov 17, 2021


444,789,186 Vaccines Administered	
228,175,638 People who received at least one dose	195,612,365 People who are fully vaccinated*
68.7% Percentage of the US population that has received at least one dose	58.9% Percentage of the US population that has been fully vaccinated*

ACL (IL+WI) FLUPCR - Pos rate (2.7%) - Nov 28, 2021




ACL Flu positivity rate – **activity trends up** (26 pos /975 samples tested)


Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, May 23, 2021 – November 20, 2021




CDC Midwest data as of: Nov 20, 2021



CSF targets positivity rate is 3.4%



The most prevalent GI bacterial target is - (Giardia 0.8%)



The most prevalent GI viral target is – (Adeno – 0.7%)

